中国P站

Atherosclerosis, the progressive buildup of plaque within the arterial walls, is the primary underlying pathology of ischemic heart disease (IHD), a leading cause of morbidity and mortality worldwide. The narrowing of coronary arteries due to atherosclerotic lesions restricts blood flow to the myocardium, leading to angina, myocardial infarction, heart failure, and sudden cardiac death. While lifestyle modifications, including dietary changes, exercise, and smoking cessation, remain fundamental in the management of atherosclerosis and IHD, the advent and continuous development of advanced medications have dramatically improved clinical outcomes. These pharmacological interventions target various aspects of the atherosclerotic process, from lipid lowering and antiplatelet activity to inflammation reduction and myocardial protection. The landscape of medications for atherosclerosis-related IHD has evolved significantly over the past few decades, moving beyond traditional therapies to include novel agents with more specific and potent mechanisms of action. This manuscript will provide a comprehensive overview of the impact of these advanced medications on atherosclerosis-related ischemic heart disease, detailing their mechanisms of action, clinical efficacy, and their role in primary and secondary prevention, ultimately highlighting their contribution to reducing cardiovascular events and improving the quality of life for patients with this prevalent condition [1].

Description

The pharmacological management of atherosclerosis-related ischemic heart disease has been revolutionized by the development of advanced medications that target key stages in the atherosclerotic process and its clinical manifestations. Lipid-lowering therapies remain a cornerstone of treatment, with statins serving as the primary agents for reducing low-density lipoprotein cholesterol (LDL-C), a major driver of atherogenesis [2]. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL-C from the circulation. Beyond their LDL-lowering effects, statins also exhibit pleiotropic benefits, including improving endothelial function, reducing inflammation, and stabilizing atherosclerotic plaques. More recently, novel lipid-lowering agents have emerged, offering additional strategies for achieving aggressive lipid targets, particularly in high-risk patients. Ezetimibe inhibits intestinal cholesterol absorption, providing a complementary mechanism to statins and further reducing LDL-C levels when used in combination. PCSK9 inhibitors, such as evolocumab and alirocumab, are monoclonal antibodies that block the proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that degrades LDL receptors. By inhibiting PCSK9, these agents significantly lower LDL-C levels, often achieving levels previously considered unattainable with statins alone, and have demonstrated substantial reductions in cardiovascular events in clinical trials. Inclisiran, a small interfering RNA (siRNA) that inhibits PCSK9 synthesis in the liver, offers a less frequent (twice-yearly) dosing schedule, improving patient adherence [3].

Antiplatelet therapies are crucial in preventing thrombotic complications of atherosclerosis, which are the immediate cause of many acute ischemic events. Aspirin, a cyclooxygenase-1 (COX-1) inhibitor, irreversibly inhibits thromboxane A2 production, thereby reducing platelet aggregation. Dual antiplatelet therapy (DAPT), typically combining aspirin with a P2Y12 receptor inhibitor such as clopidogrel, prasugrel, or ticagrelor, is often used after percutaneous coronary intervention (PCI) or in patients with acute coronary syndromes (ACS) to provide more potent platelet inhibition and reduce the risk of stent thrombosis and recurrent ischemic events. The duration of DAPT is tailored to the individual patient's risk of ischemic and bleeding events. Anticoagulants, such as warfarin and the direct oral anticoagulants (DOACs) like apixaban, rivaroxaban, edoxaban, and dabigatran, play a role in specific subsets of patients with IHD, particularly those with atrial fibrillation or a high risk of thromboembolism [4].

While not directly targeting atherosclerosis, they prevent thrombus formation in the context of underlying atherosclerotic disease. Recognizing the significant role of inflammation in the pathogenesis of atherosclerosis, novel anti-inflammatory therapies have emerged. Colchicine, an anti-inflammatory agent commonly used for gout, has shown promise in reducing cardiovascular events in patients with stable coronary artery disease and after myocardial infarction by inhibiting neutrophil activation and inflammation. Canakinumab, a monoclonal antibody targeting interleukin-1β, demonstrated a reduction in cardiovascular events in a large clinical trial, providing further evidence for the inflammatory hypothesis of atherosclerosis. However, its broad immunosuppressive effects limit its widespread use. More targeted anti-inflammatory therapies are currently under investigation [5].

Myocardial protection during acute ischemic events is another critical area of pharmacological advancement. Beta-blockers reduce heart rate and contractility, decreasing myocardial oxygen demand and limiting infarct size. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are crucial in patients with left ventricular dysfunction or after myocardial infarction, as they reduce afterload, prevent ventricular remodeling, and improve long-term outcomes [6].

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes management, have demonstrated significant cardiovascular benefits in patients with and without diabetes, including a reduction in heart failure hospitalizations and cardiovascular death, potentially through mechanisms involving improved myocardial energetics, reduced inflammation, and improved endothelial function. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), also primarily used for diabetes, have shown cardiovascular protective effects, including a reduction in major adverse cardiovascular events, possibly through mechanisms involving improved glucose control, weight loss, and direct effects on the vasculature. The ongoing research and development of novel therapeutic targets and agents promise further advancements in the pharmacological management of atherosclerosis-related ischemic heart disease, aiming for more personalized and effective strategies to combat this major global health challenge [7,8].

Conclusion

Advanced medications have profoundly impacted the management and prognosis of atherosclerosis-related ischemic heart disease. From potent lipid-lowering agents like PCSK9 inhibitors and inclisiran to sophisticated antiplatelet and antithrombotic strategies, and the emerging role of anti-inflammatory therapies, the pharmacological armamentarium has expanded significantly. The integration of these advanced medications, alongside traditional therapies and lifestyle modifications, has led to substantial reductions in cardiovascular events, improved quality of life, and increased survival rates for patients with IHD. The recognition of the multifaceted nature of atherosclerosis, involving lipid metabolism, thrombosis, and inflammation, has driven the development of therapies that target these specific pathways with greater precision and efficacy. Furthermore, the unexpected cardiovascular benefits observed with medications initially developed for other conditions, such as SGLT2 inhibitors and GLP-1 RAs, highlight the complex interplay between metabolic disorders and cardiovascular disease and offer new avenues for therapeutic intervention. As our understanding of the underlying pathophysiology of atherosclerosis continues to evolve, so too will the development of even more targeted and effective medications. Future directions in this field will likely focus on personalized medicine approaches, tailoring therapies based on individual patient risk profiles, genetic predispositions, and specific plaque characteristics. The ongoing pursuit of novel therapeutic targets and the refinement of existing medications hold immense promise for further reducing the burden of atherosclerosis-related ischemic heart disease and improving cardiovascular health on a global scale.

Acknowledgement

None

Conflict of Interest

None

References

1. Komatsu S, Yutani C, Ohara T, Takahashi S, Takewa M, et al. (2018) J Am Coll Cardiol 25: 2893-2902.

   , ,

2. Kojima K, Kimura S, Hayasaka K, Mizusawa M, Misawa T, et al. (2019) J Atherosclerosis Thromb 26: 997-1006.

   , ,

3. Nasiri M, Janoudi A, Vanderberg A, Frame M, Flegler C, et al. (2015) Microsc Res Tech 78: 969-974.

   , ,

4. Galozzi P, Bindoli S, Luisetto R, Sfriso P, Ramonda R, et al. (2021) Jul Expet Rev Clin Immunol 17: 773-787.

   , ,

5. Konikoff FM, Chung DS, Donovan JM, Small DM, Carey MC (1992) J Clin Invest 90: 1155-1160.

   , ,

6. Varsano N, Beghi F, Elad N, Pereiro E, Dadosh T, et al. (2018) Proc Natl Acad Sci Unit States Am 115: 7662-7669.

   , ,

7. Abela GS (2010) J Clin Lipidol 4: 156-164.

   , ,

8. Park S, Sut TN, Ma GJ, Parikh AN, Cho NJ (2020) J Am Chem Soc 142: 1872-1882.

   , ,